🟢 Alzamend Neuro is trading 5.3% up today as investors respond to financing

Alzamend Neuro is trading 5.3% up at $1.44 as investors continue responding to its recently announced financing.

• The initial Series D convertible preferred-stock tranche provided $7.5 million, with up to $17.5 million in additional funding available for clinical programs and working capital.
• The financing was reported as a major catalyst for the prior session’s gain, although no new August 10 announcement was identified.
• Broader markets are mixed, so the move appears primarily company-specific rather than market-driven.